上海打出“组合拳” 促进医保商保共同发展支持创新药械

Group 1 - The core viewpoint of the news is the introduction of measures by the Shanghai Financial Regulatory Bureau to promote the high-quality development of commercial health insurance, enhancing the insurance industry's ability to serve public health needs and improving the accessibility and affordability of innovative drugs and medical devices [1][2] - The measures include five main areas with 18 specific actions aimed at broadening the coverage of commercial health insurance and developing a multi-tiered product system [1] - There is a focus on developing health insurance products tailored for specific groups such as the elderly, children, and those with chronic illnesses, as well as enhancing health management services to reduce risks [1][2] Group 2 - The measures encourage the development of group health insurance products that involve employer contributions and cover innovative drug costs, aiming to establish a risk adjustment mechanism in key economic sectors [1][2] - There is an emphasis on deepening the interconnectivity of medical, health insurance, and commercial insurance data, using clinical trial data as pricing references for insurance companies [2] - The introduction of innovative payment mechanisms for new drugs and medical devices is supported, facilitating their integration into hospitals and insurance coverage, while also promoting tax deductions and funding optimization for commercial health insurance [2]